PMC9884833_01
PMC9884833_02
Depressive and anxiety symptoms scores at recruitment point and during 20 months of active DBS stimulation period. HAMA, Hamilton Anxiety Rating Scale; HDRS-17, Hamilton Depression Rating Scale 17-item version; MADRS, Montgomery-Asberg Depressive Rating Scale.
fpsyt-13-1068054-g0002.jpg
PMC9884833_02_fpsyt-13-1068054-g0002.jpg
F2
The patient also reported improvement in self-assessment VAS scales (see Figure 2). A sudden relapse of symptoms with subjective worsening of mental state (see Figure 2) and stimulation side effects were reported (hand tremors, tachycardia, vision blurring and diplopia).
SOFAS (Social and Occupational Functioning Assessment Scale) scores at recruitment point and during 20 months of active DBS stimulation period.
fpsyt-13-1068054-g0003.jpg
PMC9884833_02_fpsyt-13-1068054-g0003.jpg
F3
Visual analog scale (VAS) of self-assessment scores at recruitment point and during 20 months of active DBS stimulation period. Mood and concentration scales were scored positively (0-worst mood and concentration and 10-best mood and concentration), while anxiety and physical discomfort scales were scored negatively (0-least intensive anxiety and discomfort and 10-most intensive anxiety and discomfort).
fpsyt-13-1068054-g0004.jpg
PMC9884833_02_fpsyt-13-1068054-g0004.jpg
F4
See Figure 4 for more details.
Timeline of the treatment.
fpsyt-13-1068054-g0005.jpg
PMC9884833_02_fpsyt-13-1068054-g0005.jpg
F5
For detailed information on the treatment timeline, please see Figure 5.